Somewhat Favorable News Coverage Somewhat Unlikely to Affect Pluristem Therapeutics (PSTI) Share Price

News headlines about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.8949185948478 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s analysis:

Shares of Pluristem Therapeutics (NASDAQ PSTI) traded down $0.06 during trading on Wednesday, hitting $1.52. The company had a trading volume of 219,300 shares, compared to its average volume of 416,764. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $2.12.

Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). research analysts forecast that Pluristem Therapeutics will post -0.34 earnings per share for the current year.

PSTI has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $3.50 target price on shares of Pluristem Therapeutics in a research report on Wednesday, September 6th. Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 1st. ValuEngine lowered Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Seaport Global Securities restated a “buy” rating and set a $5.00 target price on shares of Pluristem Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $4.38.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Pluristem Therapeutics (PSTI) Share Price” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://ledgergazette.com/2017/11/29/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-pluristem-therapeutics-psti-share-price.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply